CARB-X EXPANDS AWARDS TO AMICROBE BY $4.6M TO ACCELERATE DEVELOPMENT OF TWO DISTINCT AMICIDIN-Β TOPICAL ANTIMICROBIAL PRODUCTS
CARB-X announced today it is awarding US$4.6M to Amicrobe Inc. to expand development of its bioengineered Amicidin-β synthetic protein designed to kill bacteria and cleanse tissues. The new funding will help accelerate IND-enabling work on Amicidin-β Solution, which targets treatment of serious surgical and traumatic wound infections, and will also support prototyping of a new product for prevention of infection in low- and middle-income countries (LMIC).
Under the LMIC program, Amicrobe is designing and prototyping Amicidin-β/EF (extended formulation). This new formulation of Amicidin-β, perhaps as a foam, targets ease of use and climate-zone stability in parts of the world where cold storage systems are not always available for healthcare products. Rapid, effective tissue coverage is also a critical design goal. Funding for the LMIC product is made possible by the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), a CARB-X partner that supports early-stage innovative research in underfunded areas of R&D to tackle antimicrobial resistance (AMR) for the benefit of people in LMICs.
Display your AMR technology / product:
Global AMR Technologies Database
- Preventive – Diagnostic – Antimicrobial technologies
- Academia – Research Institutes – Start ups – SMEs – Multinationals
- Early research <-> near market
- Global reach for funding / co-development / licensing